{"count": 7, "results": [{"_id": "36980186", "pmid": 36980186, "pmcid": "PMC10047033", "title": "Sestrin2 Mediates Metformin Rescued the Age-Related Cardiac Dysfunctions of Cardiorenal Syndrome Type 3", "journal": "Cells", "authors": ["Iglesias M", "Wang H", "Krause-Hauch M", "Ren D", "Zoungrana LI", "Li Z", "Zhang J", "Wei J", "Yadav N", "Patel K", "Fatmi MK", "Liu R", "Lesnefsky EJ", "Li J"], "date": "2023-03-08T00:00:00Z", "doi": "10.3390/cells12060845", "meta_date_publication": "2023 Mar 8", "meta_volume": "12", "meta_issue": "6", "meta_pages": "", "score": 50264.035, "text_hl": "However, the role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@CRS3@@@ remains unknown. ", "citations": {"NLM": "Iglesias M, Wang H, Krause-Hauch M, Ren D, Zoungrana LI, Li Z, Zhang J, Wei J, Yadav N, Patel K, Fatmi MK, Liu R, Lesnefsky EJ, Li J. Sestrin2 Mediates Metformin Rescued the Age-Related Cardiac Dysfunctions of Cardiorenal Syndrome Type 3 Cells. 2023 Mar 8;12(6):. PMID: 36980186", "BibTeX": "@article{36980186, title={Sestrin2 Mediates Metformin Rescued the Age-Related Cardiac Dysfunctions of Cardiorenal Syndrome Type 3}, author={Iglesias M and Wang H and Krause-Hauch M and Ren D and Zoungrana LI and Li Z and Zhang J and Wei J and Yadav N and Patel K and Fatmi MK and Liu R and Lesnefsky EJ and Li J}, journal={Cells}, volume={12}, number={6}}"}}, {"_id": "37468901", "pmid": 37468901, "pmcid": "PMC10354939", "title": "2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes", "journal": "Diabetol Metab Syndr", "authors": ["Bertoluci MC", "Silva Júnior WS", "Valente F", "Araujo LR", "Lyra R", "de Castro JJ", "Raposo JF", "Miranda PAC", "Boguszewski CL", "Hohl A", "Duarte R", "Salles JEN", "Silva-Nunes J", "Dores J", "Melo M", "de Sá JR", "Neves JS", "Moreira RO", "Malachias MVB", "Lamounier RN", "Malerbi DA", "Calliari LE", "Cardoso LM", "Carvalho MR", "Ferreira HJ", "Nortadas R", "Trujilho FR", "Leitão CB", "Simões JAR", "Dos Reis MIN", "Melo P", "Marcelino M", "Carvalho D"], "date": "2023-07-19T00:00:00Z", "doi": "10.1186/s13098-023-01121-x", "meta_date_publication": "2023 Jul 19", "meta_volume": "15", "meta_issue": "1", "meta_pages": "160", "score": 50259.44, "text_hl": "In treatment naive @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@ individuals without @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@cardiorenal complications@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is the agent of choice when HbA1c is 7.5% or below. ", "citations": {"NLM": "Bertoluci MC, Silva Júnior WS, Valente F, Araujo LR, Lyra R, de Castro JJ, Raposo JF, Miranda PAC, Boguszewski CL, Hohl A, Duarte R, Salles JEN, Silva-Nunes J, Dores J, Melo M, de Sá JR, Neves JS, Moreira RO, Malachias MVB, Lamounier RN, Malerbi DA, Calliari LE, Cardoso LM, Carvalho MR, Ferreira HJ, Nortadas R, Trujilho FR, Leitão CB, Simões JAR, Dos Reis MIN, Melo P, Marcelino M, Carvalho D. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes Diabetol Metab Syndr. 2023 Jul 19;15(1):160. PMID: 37468901", "BibTeX": "@article{37468901, title={2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes}, author={Bertoluci MC and Silva Júnior WS and Valente F and Araujo LR and Lyra R and de Castro JJ and Raposo JF and Miranda PAC and Boguszewski CL and Hohl A and Duarte R and Salles JEN and Silva-Nunes J and Dores J and Melo M and de Sá JR and Neves JS and Moreira RO and Malachias MVB and Lamounier RN and Malerbi DA and Calliari LE and Cardoso LM and Carvalho MR and Ferreira HJ and Nortadas R and Trujilho FR and Leitão CB and Simões JAR and Dos Reis MIN and Melo P and Marcelino M and Carvalho D}, journal={Diabetol Metab Syndr}, volume={15}, number={1}, pages={160}}"}}, {"_id": "38503370", "pmid": 38503370, "title": "Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.", "journal": "Int J Biol Macromol", "authors": ["Harada M", "Han S", "Shi M", "Ge J", "Yu S", "Adam J", "Adamski J", "Scheerer MF", "Neschen S", "de Angelis MH", "Wang-Sattler R"], "date": "2024-03-17T00:00:00Z", "doi": "10.1016/j.ijbiomac.2024.130962", "meta_date_publication": "2024 Mar 17", "meta_volume": "265", "meta_issue": "Pt 1", "meta_pages": "130962", "score": 50250.406, "text_hl": "Combining a Sodium-Glucose-Cotransporter-2-inhibitor (SGLT2i) with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is recommended for managing @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ (@DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@) who have @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@cardio-renal complications@@@. ", "citations": {"NLM": "Harada M, Han S, Shi M, Ge J, Yu S, Adam J, Adamski J, Scheerer MF, Neschen S, de Angelis MH, Wang-Sattler R. Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice. Int J Biol Macromol. 2024 Mar 17;265(Pt 1):130962. PMID: 38503370", "BibTeX": "@article{38503370, title={Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.}, author={Harada M and Han S and Shi M and Ge J and Yu S and Adam J and Adamski J and Scheerer MF and Neschen S and de Angelis MH and Wang-Sattler R}, journal={Int J Biol Macromol}, volume={265}, number={Pt 1}, pages={130962}}"}}, {"_id": "34962662", "pmid": 34962662, "title": "Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.", "journal": "Diabet Med", "authors": ["Sim R", "Chong CW", "Loganadan NK", "Fong AYY", "Navaravong L", "Hussein Z", "Khunti K", "Lee SWH"], "date": "2022-03-01T00:00:00Z", "doi": "10.1111/dme.14780", "meta_date_publication": "2022 Mar", "meta_volume": "39", "meta_issue": "3", "meta_pages": "e14780", "score": 50226.285, "text_hl": "CONCLUSIONS: SGLT2i and @GENE_GLP1R @GENE_2740 @@@GLP1RA@@@ were associated with lower risk for different @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@cardiorenal@@@ end points, when used as an adjunct to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in people with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@. ", "citations": {"NLM": "Sim R, Chong CW, Loganadan NK, Fong AYY, Navaravong L, Hussein Z, Khunti K, Lee SWH. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. Diabet Med. 2022 Mar;39(3):e14780. PMID: 34962662", "BibTeX": "@article{34962662, title={Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.}, author={Sim R and Chong CW and Loganadan NK and Fong AYY and Navaravong L and Hussein Z and Khunti K and Lee SWH}, journal={Diabet Med}, volume={39}, number={3}, pages={e14780}}"}}, {"_id": "18761646", "pmid": 18761646, "title": "Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance.", "journal": "Pediatr Diabetes", "authors": ["Burgert TS", "Duran EJ", "Goldberg-Gell R", "Dziura J", "Yeckel CW", "Katz S", "Tamborlane WV", "Caprio S"], "date": "2008-12-01T00:00:00Z", "doi": "10.1111/j.1399-5448.2008.00434.x", "meta_date_publication": "2008 Dec", "meta_volume": "9", "meta_issue": "6", "meta_pages": "567-76", "score": 50047.902, "text_hl": "Thus, long-term treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ may provide a means to ameliorate the @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@cardio-metabolic@@@ consequences of adolescent @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obesity@@@.", "citations": {"NLM": "Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008 Dec;9(6):567-76. PMID: 18761646", "BibTeX": "@article{18761646, title={Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance.}, author={Burgert TS and Duran EJ and Goldberg-Gell R and Dziura J and Yeckel CW and Katz S and Tamborlane WV and Caprio S}, journal={Pediatr Diabetes}, volume={9}, number={6}, pages={567-76}}"}}, {"_id": "11126985", "pmid": 11126985, "title": "[Clinically important effects of oral antidiabetic drug interactions].", "journal": "Pol Merkur Lekarski", "authors": ["Drzewoski J", "Kopff B"], "date": "2000-09-01T00:00:00Z", "meta_date_publication": "2000 Sep", "meta_volume": "9", "meta_issue": "51", "meta_pages": "605-7", "score": 50047.406, "text_hl": "Currently the most controversial problem is safety of combination therapy with @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulphonylurea@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, as several observations indicated that it can increase mortality from @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@cardio@@@-@DISEASE_Vascular_System_Injuries @DISEASE_MESH:D057772 @@@vascular@@@ causes.", "citations": {"NLM": "Drzewoski J, Kopff B. [Clinically important effects of oral antidiabetic drug interactions]. Pol Merkur Lekarski. 2000 Sep;9(51):605-7. PMID: 11126985", "BibTeX": "@article{11126985, title={[Clinically important effects of oral antidiabetic drug interactions].}, author={Drzewoski J and Kopff B}, journal={Pol Merkur Lekarski}, volume={9}, number={51}, pages={605-7}}"}}, {"_id": "21572014", "pmid": 21572014, "title": "Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.", "journal": "Am J Physiol Heart Circ Physiol", "authors": ["Yin M", "van der Horst IC", "van Melle JP", "Qian C", "van Gilst WH", "Silljé HH", "de Boer RA"], "date": "2011-08-01T00:00:00Z", "doi": "10.1152/ajpheart.00054.2011", "meta_date_publication": "2011 Aug", "meta_volume": "301", "meta_issue": "2", "meta_pages": "H459-68", "score": 50047.25, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is the first choice drug for the treatment of @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@, but its use is debated in @SPECIES_9606 @@@patients@@@ with advanced @<m>DISEASE_Cardio_Renal_Syndrome</m> @DISEASE_MESH:D059347 @@@cardiorenal disease@@@. ", "citations": {"NLM": "Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, de Boer RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H459-68. PMID: 21572014", "BibTeX": "@article{21572014, title={Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.}, author={Yin M and van der Horst IC and van Melle JP and Qian C and van Gilst WH and Silljé HH and de Boer RA}, journal={Am J Physiol Heart Circ Physiol}, volume={301}, number={2}, pages={H459-68}}"}}]}